Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma

Glofitamab, a novel CD20xCD3, T-cell–engaging bispecific antibody, exhibited single-agent activity in Study NP30179, a first-in-human, phase 1 trial in relapsed/refractory B-cell non-Hodgkin lymphoma. Preclinical studies showed that glofitamab leads to T-cell activation, proliferation, and tumor cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Bröske, Ann-Marie E., Korfi, Koorosh, Belousov, Anton, Wilson, Sabine, Ooi, Chia-Huey, Bolen, Christopher R., Canamero, Marta, Alcaide, Enrique Gomez, James, Ian, Piccione, Emily C., Carlile, David J., Dimier, Natalie, Umaña, Pablo, Bacac, Marina, Weisser, Martin, Dickinson, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945294/
https://www.ncbi.nlm.nih.gov/pubmed/34941996
http://dx.doi.org/10.1182/bloodadvances.2021005954

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945294/
https://www.ncbi.nlm.nih.gov/pubmed/34941996
http://dx.doi.org/10.1182/bloodadvances.2021005954

Ejemplares similares